AL 102 (previously known as BMS 986115), was developed as an orally active a gamma-secretase and pan-Notch inhibitor. The drug participated in phase I clinical trials in solid tumor patients. The drug was safe and well-tolerated and stabilized disease for more than six months in 14% of patients, however, Bristol-Myers Squibb terminated the study because of the changes in the business objectives. Ayala, an Israeli biotech company, licensed rights for the development of AL 102 from Bristol-Myers Squibb. In December 2018, Ayala in collaborating with Novartis decided to investigate AL102 for treatment of multiple myeloma. Ayala studied AL102, an inhibitor of the Notch pathway, in blood cancers. It is known that the pathway regulates cell-fate determination during development and maintains adult tissue balance. Cumulative evidence indicates that Notch is overactive in multiple myeloma and participates in its onset and progression.